Harboring EGFR Common Mutation
1 clinical trials · Condition
◉ Watch Harboring EGFR Common Mutation
| Record | Firm | Date |
|---|---|---|
| JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations (NCT06391944) | Shanghai JMT-Bio Inc. | 2021-11-21 |
Track Harboring EGFR Common Mutation automatically
Every clearance here is in the API, with alerts when new ones post.